Inventaire - your friends and communities are your best library

Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer

author

Vidyalakshmi Sethunath

Carmine De Angelis

Tao Wang

Obi Griffith

Laura M Heiser

Susan Hilsenbeck

Rachel Schiff

Joe W Gray

published in: Molecular Cancer Research

date of publication: 2019-08-16

Cites articles 52

Date

Title

Authors

2018-09-06

Lipophilic statins antagonistically alter the major epithelial-to-mesenchymal transition signaling pathways in breast cancer stem-like cells via inhibition of the mevalonate pathway

Siamak Salami
2018-05-15

Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling.

Alan Wells
2017-10-11

The cholesterol metabolite 27 hydroxycholesterol facilitates breast cancer metastasis through its actions on immune cells

Michael Dee Gunn, Erik R Nelson
2017-07-04

De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

Jamunarani Veeraraghavan, Carmine De Angelis, Tomás Pascual, Rachel Schiff
2017-04-21

The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis
2017-04-03

Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.

Gennaro Ciliberto, Claudia De Vitis, Giovanni Sorrentino, Daniela Trisciuoglio, Donatella Del Bufalo, Marta Di Martile, Susan Costantini, Alfredo Budillon
2017-02-24

HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

Javier Cortes, Serafin Morales, Mafalda Oliveira
2016-06-01

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer

Sunil Pancholi, Marketa J Zvelebil, Ricardo C Ribas, Andrew Thompson, Mitch Dowsett
2016-04-01

PI3K/Akt promotes feedforward mTORC2 activation through IKKα

Ricardo J Antonia
2016

Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
2015-09-21

Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma

Jaejun Shim, Cristian Rodriguez-Aguayo, Rajesha Rupaimoole, Rory Johnson, Gordon B. Mills, Anil Sood
2015-09-02

Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors

Valerie M Weaver
2015-01-01

PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
2015-01-01

Targeting HER2 for the treatment of breast cancer

Rachel Schiff
2014-10-01

The biology of YAP/TAZ: hippo signaling and beyond

Sirio Dupont, Michelangelo Cordenonsi
2014-06-19

KRAS and YAP1 converge to regulate EMT and tumor survival

Wen Xue, Joseph Rosenbluh, William C Hahn, David E Root, Anna C Schinzel, Federica Piccioni, Tyler Jacks
2014-06-19

Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer

Lynda Chin, Randy L Johnson, Ronald A. DePinho, Huamin Wang, Giulio F Draetta
2014-03-23

Metabolic control of YAP and TAZ by the mevalonate pathway

Valeria Specchia, Miguel Mano, Sirio Dupont, Silvano Piazza, Antonio Rosato, Giovanni Sorrentino, Michelangelo Cordenonsi, Roberta Sommaggio, Giannino Del Sal
2014-01-07

Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility
2013-04-12

Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling cascade.
2013-04-08

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

Rachel Schiff, Matthew P Goetz
2013-04-04

Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases
2012-10-23

PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells

Elizabeth Iorns
2012-09-07

Simvastatin inhibition of mevalonate pathway induces apoptosis in human breast cancer cells via activation of JNK/CHOP/DR5 signaling pathway
2012-08-13

The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain

Richard Hynes
2011-11-28

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

Rachel Schiff
2011-10-24

Targeting protein prenylation for cancer therapy
2011-08-31

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

Rachel Schiff, Mina Bissell
2011-06-08

Role of YAP/TAZ in mechanotransduction
2010-12-16

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer

Ingunn Holen
2010-12-15

mTOR: from growth signal integration to cancer, diabetes and ageing

Alejo Efeyan, David M. Sabatini
2010-12-07

Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts

Suleiman Massarweh, Rachel Schiff

Article - wd:Q92667609

Welcome to Inventaire

the library of your friends and communities

learn more